Cisplatin in the treatment of recurrent childhood primary brain tumors.
Thirty-three patients were treated with intravenous (IV) cisplatin (CPDD) of whom 32 were considered evaluable. There were 14 medulloblastomas, five primitive neuroectodermal tumors (PNET), nine gliomas, three ependymomas, and one germ cell tumor. The overall response rate was 13 of 32 (41%). Eleven responses (five complete [CR], five partial [PR], one mixed [MR]) were noted in the patients with medulloblastoma. The response rate within this group was 79%. Toxicity was tolerable, although it precluded further therapy in five patients.
Walker
R W
RW
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Allen
J C
JC
D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy
D002945:Cisplatin